Valuation: InMode Ltd.

Market Cap 951M 832M 767M 710M 1.35B 90.78B 1.37B 9.19B 3.6B 44.58B 3.57B 3.49B 154B P/E 2026 *
13x
P/E 2027 * 11.7x
Enterprise Value 951M 832M 767M 710M 1.35B 90.78B 1.37B 9.19B 3.6B 44.58B 3.57B 3.49B 154B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 2.51x
Free-Float
60.55%
Yield 2026 *
-
Yield 2027 * -
1 day-0.16%
1 week-1.58%
Current month-2.08%
1 month+8.33%
3 months+7.77%
6 months+3.05%
Current year+0.93%
1 week 12.49
Extreme 12.49
12.75
1 month 11.38
Extreme 11.375
12.96
Current year 11.02
Extreme 11.02
13.88
1 year 11.02
Extreme 11.02
13.88
3 years 11.02
Extreme 11.02
41.52
5 years 11.02
Extreme 11.02
41.52
10 years 11.02
Extreme 11.02
41.52
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2008-01-01
Chief Executive Officer 73 2008-01-01
Director of Finance/CFO 41 2026-05-18
Director TitleAgeSince
Chairman 73 2008-01-01
Director/Board Member 59 2019-08-06
Chairman 67 2026-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-0.16%-1.58% - - 951M
+2.86%+0.24%+24.97%+2.14% 195B
-0.86%-3.39%-22.07%+24.23% 146B
+0.40%-0.33%-56.30%-13.96% 66.87B
-2.47%-3.22%+18.32%+1.19% 52.59B
+0.38%-1.66%-27.47%-30.66% 43.85B
+3.50%+2.22%+10.13%+14.18% 37.73B
+2.44%-0.57%+8.00%+42.77% 37.03B
+1.27%-0.56%-18.57%-3.41% 30.07B
+0.03%-1.32%-14.32%-18.74% 29.43B
Average +0.81%-1.89%-8.59%+1.97% 70.92B
Weighted average by Cap. +1.12%-1.81%-4.16%+5.01%

Financials

2026 *2027 *
Net sales 370M 324M 299M 276M 524M 35.32B 533M 3.57B 1.4B 17.34B 1.39B 1.36B 60.08B 379M 332M 306M 283M 537M 36.2B 546M 3.66B 1.44B 17.78B 1.42B 1.39B 61.58B
Net income 72.82M 63.7M 58.74M 54.35M 103M 6.95B 105M 703M 276M 3.41B 273M 267M 11.82B 78.85M 68.98M 63.61M 58.85M 112M 7.53B 114M 762M 299M 3.7B 296M 290M 12.8B
Net Debt - -
Logo InMode Ltd.
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Employees
660
Date Price Change
26-07-09 €12.49 -0.16%
26-07-08 €12.51 -0.60%
26-07-07 €12.59 -1.29%
26-07-06 €12.75 -0.08%
26-07-03 €12.76 +0.55%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
15.01USD
Average target price
14.33USD
Spread / Average Target
-4.51%

Quarterly revenue - Rate of surprise